Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
5-day change
1st Jan Change
19.98
USD
+3.90%
+8.71%
-5.89%
Presentation Operator MessageOperator (Operator)Good afternoon, and thank you for standing by....
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
BTIG Cuts Price Target on Xencor to $38 From $56, Keeps Buy Rating
Apr. 16
MT
Xencor Names Bart Cornelissen as Chief Financial Officer
Apr. 09
MT
Xencor, Inc. Announces CFO Changes
Apr. 09
CI
Xencor Appoints Bart Cornelissen as Senior Vice President
Apr. 09
CI
Transcript : Xencor, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 11:15 AM
Mar. 14
Xencor Insider Sold Shares Worth $293,519, According to a Recent SEC Filing
Mar. 07
MT
North American Morning Briefing : Fed's Preferred -2-
Feb. 29
DJ
Wedbush Adjusts Xencor's Price Target to $34 From $36, Keeps Outperform Rating
Feb. 28
MT
Transcript : Xencor, Inc., Q4 2023 Earnings Call, Feb 27, 2024
Feb. 27
Earnings Flash (XNCR) XENCOR Posts Q4 Revenue $44.7M, vs. Street Est of $74.7M
Feb. 27
MT
Xencor, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Feb. 27
CI
Xencor Insider Sold Shares Worth $1,048,743, According to a Recent SEC Filing
Feb. 14
MT
Transcript : Xencor, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:45 PM
Jan. 10
Xencor, Inc. Appoints Dane Leone as Senior Vice President, Corporate Strategy
Jan. 02
CI
Xencor Insider Sold Shares Worth $941,670, According to a Recent SEC Filing
Dec. 29
MT
Xencor, Inc. Enters into an Amended and Restated Collaboration and License Agreement with Genentech, Inc
Nov. 15
CI
RBC Cuts Price Target on Xencor to $32 From $36, Keeps Outperform, Speculative Risk
Nov. 08
MT
Wedbush Trims Xencor's PT to $36 From $37 After Stopping XmAb104 Development, Opting Out of Cost Sharing With Genentech to Co-develop XmAb306; Maintains Outperform Rating
Nov. 08
MT
Transcript : Xencor, Inc., Q3 2023 Earnings Call, Nov 07, 2023
Nov. 07
Earnings Flash (XNCR) XENCOR Reports Q3 Revenue $59.2M, vs. Street Est of $30M
Nov. 07
MT
Xencor, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 07
CI
Xencor, Inc. and OCM Life Sciences Portfolio LP, Entere into A Royalty Purchase Agreement
Nov. 07
CI
Xencor Says Cancer Drug Candidates Showed Anti-Tumor Activity in Preclinical Trials
Nov. 03
MT
Xencor Says CFO John Kuch to Retire in March
23-10-26
MT
John J. Kuch to Retire as Chief Financial Officer of Xencor, Inc. in March 2024
23-10-26
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, and Novartis XmAb undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of fbalropendekin alfa (XmAb306/RG6323), XmAb564, and XmAb662. Its other clinical-stage drug candidates consist of Obexelimab, AIMab7195 (XmAb7195), and Xpro1595. Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
More about the company
Last Close Price
19.98
USD
Average target price
36.18
USD
Spread / Average Target
+81.09%
Consensus
1st Jan change
Capi.
-5.89% 1.23B -2.31% 103B +0.56% 95.28B +1.69% 22.15B -17.37% 21.02B -9.30% 18.15B -41.01% 16.74B -14.85% 16.05B +3.21% 13.68B +33.54% 12.17B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1